SCHEMBL11943885

SCHEMBL11943885

CCCCCCCOc1c(N2CCN(S(=O)(=O)Cc3cccc(C(F)(F)F)c3)CC2)cnn(-c2ccccc2)c1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.48
▸ ALDH1A1 P00352 4/20 0.41
▸ DCTPP1 Q9H773 1/20 0.41
▸ HTT P42858 1/20 0.39
▸ HSD11B1 P28845 1/20 0.39
▸ NPBWR1 P48145 1/20 0.38
▸ MCHR1 Q99705 1/20 0.38
▸ SMO Q99835 1/20 0.38
▸ GALR3 O60755 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ POLB P06746 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ PPARG P37231 1/20 0.36
▸ NCOA2 Q15596 1/20 0.36
▸ NCOA1 Q15788 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ NCOA3 Q9Y6Q9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11945003 0.92 MAPT (0.50) MAPTALDH1A1DCTPP1HSD11B1NPBWR1
SCHEMBL11943866 0.90 MAPT (0.56) MAPTALDH1A1DCTPP1LMNAKMT2A
SCHEMBL11944989 0.86 MAPT (0.52) MAPTALDH1A1DCTPP1LMNAKMT2A
SCHEMBL11943867 0.85 MAPT (0.64) MAPTALDH1A1DCTPP1LMNAKMT2A
SCHEMBL11944004 0.85 MAPT (0.47) MAPTALDH1A1DCTPP1HSD11B1LMNA
SCHEMBL11943871 0.85 MAPT (0.55) MAPTALDH1A1DCTPP1LMNAKMT2A
SCHEMBL11944987 0.84 MAPT (0.57) MAPTALDH1A1DCTPP1NPBWR1LMNA
SCHEMBL11944008 0.83 MAPT (0.45) MAPTALDH1A1DCTPP1HSD11B1LMNA
SCHEMBL11943879 0.83 MAPT (0.52) MAPTALDH1A1DCTPP1LMNAKMT2A
SCHEMBL11943882 0.83 MAPT (0.51) MAPTALDH1A1DCTPP1LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA MAPT 2295/4885ALDH1A1 2437/4885DCTPP1 625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback